SCHEMBL30482369

SCHEMBL30482369

Cc1ccc(NC(=O)OC(C)(C)C)c2c(=O)n(Cc3ccccc3C(F)(F)F)nnc12

nearest known ligand 0.47

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ HSD17B13 Q7Z5P4 13/20 0.47
▸ LMNA P02545 1/20 0.41
▸ POLB P06746 1/20 0.41
▸ NPBWR1 P48145 1/20 0.38
▸ P2RY14 Q15391 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ GAA P10253 1/20 0.37
▸ ATM Q13315 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37
▸ TDP1 Q9NUW8 1/20 0.37
▸ CNR2 P34972 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30482368 1.00 HSD17B13 (0.47) HSD17B13LMNAPOLBNPBWR1P2RY14
SCHEMBL31501594 0.91 HSD17B13 (0.46) HSD17B13LMNAPOLBNPBWR1P2RY14
SCHEMBL25431548 0.89 HSD17B13 (0.51) HSD17B13NPBWR1P2RY14KDM4EALDH1A1
SCHEMBL25373979 0.80 HSD17B13 (0.61) HSD17B13
SCHEMBL25377690 0.79 HSD17B13 (0.76) HSD17B13
SCHEMBL30482346 0.79 HSD17B13 (0.76) HSD17B13
SCHEMBL25431886 0.78 NPBWR1 (0.42) HSD17B13NPBWR1KDM4EALDH1A1GAA
SCHEMBL30482284 0.78 NPBWR1 (0.42) HSD17B13NPBWR1KDM4EALDH1A1GAA
SCHEMBL26230068 0.78 NPBWR1 (0.42) HSD17B13NPBWR1KDM4EALDH1A1GAA
SCHEMBL26230397 0.71 HSD17B13 (0.45) HSD17B13LMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4469451-A1 2-SUBSTITUTED THIAZOLE HSD17B13 INHIBITORS AND USES THEREOF Inipharm, Inc. (US) 2024-12-04 — — EP disclosed
WO-2023146897-A1 2-SUBSTITUTED THIAZOLE HSD17B13 INHIBITORS AND USES THEREOF INIPHARM, INC. (US) 2023-08-03 — — WO disclosed
Send feedback